CHEK2 and prostate carcinoma: Recently, Cybulski et al. (2013) further investigated that four variants of CHEK2, including 1100delC mutation on risk and progression using expanded 3,750 Polish unselected prostate cancer patients, 412 familial cases, and 3,956 controls.